Crackdown on illegal weight loss drugs

The main request is stronger, visible enforcement against unregistered and illegally distributed weight-loss products. Leaders say open sales through social media and wellness businesses put patients at risk and can make unlawful products appear legitimate. They want authorities to act against both public-facing sellers and more organised supply networks.

Stavros Nicolaou specifically called for seizures, arrests and prosecutions involving products marketed as retatrutide. Sara Norcross also urged authorities to publicise enforcement and educate the public about misleading claims. Industry groups said they report suspected suppliers, send cease and desist letters and pursue legal action.

SAHPRA said regulations exist, but enforcement is difficult and criminal cases may depend on other institutions. The National Prosecuting Authority is involved in discussions about case handling. Nicolaou said the new government and industry task force would address these concerns, but enforcement remains essential.

Retatrutide is a treatment still being studied by US pharmaceutical company Eli Lilly. The article describes it as investigational because it remains in clinical development and has not been presented as generally approved for public sale. Its status matters because products sold outside controlled clinical trials may not be legitimate retatrutide or authorised medicines.

Eli Lilly says retatrutide is available only to participants in its clinical trials. The company has warned people against products marketed or sold outside those trials. Despite that warning, Nicolaou identified retatrutide-labelled products as a priority for enforcement in South Africa.

The article does not detail the approval process or the product’s medical results. It does show the practical distinction between a trial treatment and a medicine supplied through normal channels. Authorities and industry want action against sellers who use the name to market unregistered products.

Using the article’s distinct examples, seven channels or movement routes are described. They are social media, wellness businesses, sophisticated distribution networks, healthcare professionals, informal channels, consignments misleadingly declared as cosmetics, and medicines carried in travellers’ luggage. The article also calls some sales openly advertised, but that describes visibility rather than a separate route.

For example, products may be promoted through social media or wellness businesses, while other supplies move through organised networks. Some healthcare professionals may supply suspect products. At the border, importers may declare medicines as cosmetics, and travellers may carry them in luggage. Customs systems and intelligence are used to identify these routes.

This count is a way of grouping the article’s examples, not an official industry statistic. The overlap matters because one product can be advertised informally, supplied by a professional and moved through a misleading customs declaration. Enforcement therefore requires cooperation across several agencies.

Using an unregistered or counterfeit weight-loss product can put patients at risk because the article does not establish that the product is genuine, authorised or supplied under proper controls. Patients may also be misled by claims that make a suspect product look like a legitimate prescription medicine. The article links these sales directly to patient safety concerns.

Sara Norcross warned that visible sellers could make consumers assume their products were legitimate. She also highlighted healthcare professionals supplying suspect products, which complicates advice to obtain medicines through a trusted doctor or pharmacy. Products marketed as retatrutide outside Eli Lilly’s trials were specifically criticised.

The article does not list particular injuries or side effects. It does show wider consequences: patients may lose confidence in legitimate sources, while illegal sellers gain credibility. Public education, enforcement and professional oversight are intended to steer patients toward authorised care and supply channels.

Several South African institutions share responsibility because illegal medicine sales involve regulation, borders, money, criminal cases and professional conduct. SAHPRA handles medicines regulation and compliance. The Border Management Authority checks movement across borders. SARS investigates customs, tax and financial information. The National Prosecuting Authority supports the handling of criminal cases.

SAHPRA said it opens criminal cases and works with other agencies. The Border Management Authority and SARS use intelligence, import documents and risk systems to identify suspicious consignments. The South African Pharmacy Council addresses pharmacy compounding and warns against pharmacies operating as manufacturers. The Health Professions Council of South Africa investigates complaints against practitioners.

Possible outcomes include seizures, arrests and prosecutions. Practitioners may face suspension while an inquiry proceeds, or suspension or removal from the register after findings. Pharmaceutical companies also report suspected suppliers, issue cease and desist letters and take legal action. The article presents cooperation as necessary because no single institution controls every stage.

Border and customs officials look for inconsistencies between what a shipment is declared to contain and what it actually contains. The Border Management Authority uses intelligence and risk assessments to identify suspicious consignments. Officials compare their contents with import documents and seek SAHPRA’s technical assistance when specialist medicine knowledge is needed.

Some medicines are allegedly brought into South Africa under misleading declarations, including as cosmetics. SARS uses electronic import declarations and an automated risk assessment system. Its system draws on information from SAHPRA and other authorities to flag suspicious consignments. Officials also worry about medicines carried by travellers rather than shipped commercially.

The Border Management Authority is exploring whether dogs could be trained to detect these medicines, alongside existing capabilities. SARS also wants intelligence about suspected sellers so it can investigate income, tax affairs and asset growth. These methods connect border detection with financial investigations and regulatory action.

Medicines are normally tested and registered before public sale so authorities can assess what they are, whether they meet required standards and whether their use is appropriately controlled. Professional oversight adds a trusted route for prescribing, supplying and advising patients. These safeguards matter because the article warns that unregistered, counterfeit and illegally distributed products can put patients at risk.

The article contrasts legitimate supply through a trusted doctor or pharmacy with informal sales and suspect products. Eli Lilly says retatrutide is limited to clinical-trial participants, while products sold outside those trials are not endorsed by the company. The South African Pharmacy Council also stresses that compounding is for individual patients on prescriptions, not unrestricted manufacturing.

The source does not explain the technical testing or registration steps. It does show why the system matters: regulation supports patient protection, clearer accountability and public confidence. Stronger enforcement is intended to keep medicines within those controlled pathways.